{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:36:59Z","timestamp":1794109019681,"version":"4.8.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021778","name":"Agencia Nacional De Promoci\u00f3n Cient\u00edfica Y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-2021-I-A-00887"],"award-info":[{"award-number":["PICT-2021-I-A-00887"]}],"id":[{"id":"10.13039\/501100021778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007351","name":"Universidad de Buenos Aires Secretar\u00eda de Ciencia y T\u00e9cnica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PIP 112-202001-01544"],"award-info":[{"award-number":["PIP 112-202001-01544"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005363","name":"Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["20020170100067BA"],"award-info":[{"award-number":["20020170100067BA"]}],"id":[{"id":"10.13039\/501100005363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115885","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:12:09Z","timestamp":1697458329000},"page":"115885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["An updated review of chemical compounds with anti-Toxoplasma gondii activity"],"prefix":"10.1016","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5180-096X","authenticated-orcid":false,"given":"Juan B.","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio H.","family":"Szajnman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejmech.2023.115885_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1471-4922(01)02093-1","article-title":"Toxoplasmosis: a persisting challenge","volume":"17","author":"L\u00fcder","year":"2001","journal-title":"Trends Parasitol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1863-2378.2009.01276.x","article-title":"A brief history and overview of Toxoplasma gondii","volume":"57","author":"Innes","year":"2010","journal-title":"Zoon. Public Health"},{"issue":"Suppl","key":"10.1016\/j.ejmech.2023.115885_bib3","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1093\/clinids\/17.Supplement_2.S423","article-title":"Toxoplasmosis in patients with cancer","volume":"17","author":"Israelski","year":"1993","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1039\/B610213C","article-title":"Fluorine in medicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2023.115885_bib5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/1471-2105-7-382","article-title":"MultiSeq: unifying sequence and structure data for evolutionary analysis","volume":"7","author":"Roberts","year":"2006","journal-title":"BMC Bioinf."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/clinids\/18.6.853","article-title":"Toxoplasmosis in pregnancy","volume":"18","author":"Wong","year":"1994","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1590\/S0074-02762009000200029","article-title":"Why prevent, diagnose and treat congenital toxoplasmosis?","volume":"104","author":"McLeod","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib8","first-page":"1","article-title":"Ocular toxoplasmosis: a global reassessment: part II: disease manifestations and management","volume":"137","author":"Holland","year":"2004","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ophtha.2012.07.061","article-title":"Interventions for Toxoplasma retinochoroiditis","volume":"120","author":"Kim","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0161-6420(02)00990-9","article-title":"Ocular toxoplasmosis","volume":"109","author":"Bosch-Driessen","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2023.115885_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115130","article-title":"Estimations of the number people with mental diseases associated with toxoplasmosis and identification of risk factors by continent","volume":"323","author":"Nessim","year":"2023","journal-title":"Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00115-19","article-title":"Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis","volume":"34","author":"Elsheikha","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/13543776.2012.668886","article-title":"New antibacterials for the treatment of toxoplasmosis; a patent review","volume":"22","author":"Rodriguez","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/INF.0000000000001120","article-title":"Treatment of congenital toxoplasmosis","volume":"35","author":"Teil","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115885_bib15","doi-asserted-by":"crossref","first-page":"17627","DOI":"10.1021\/acs.jmedchem.1c01569","article-title":"Chemotherapeutics for Toxoplasma gondii: molecular biotargets, binding modes, and structure\u2013activity relationship investigations","volume":"64","author":"Wu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115885_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/DDDT.S60973","article-title":"Drugs in development for toxoplasmosis: advances, challenges, and current status","volume":"2017","author":"Alday","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1550-7408.1980.tb04228.x","article-title":"A newly revised classification of the protozoa","volume":"27","author":"Levine","year":"1980","journal-title":"J. Protozool."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01155-15","article-title":"Novel Approaches Reveal that Toxoplasma gondii bradyzoites within tissue cysts are dynamic and replicating entities in vivo","volume":"6","author":"Watts","year":"2015","journal-title":"mBio"},{"issue":"6658","key":"10.1016\/j.ejmech.2023.115885_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/37132","article-title":"A plastid organelle as a drug target in apicomplexan parasites","volume":"390","author":"Fichera","year":"1997","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mib.2006.06.017","article-title":"Pulling together: an integrated model of Toxoplasma cell invasion","volume":"10","author":"Carruthers","year":"2007","journal-title":"Curr. Op. Microbiol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/CMR.11.2.267","article-title":"Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts","volume":"11","author":"Dubey","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3181\/00379727-51-13809","article-title":"Therapeutic effectiveness of certain sulfonamides on infection by an intracellular protozoon (Toxoplasma)","volume":"51","author":"Sabin","year":"1942","journal-title":"Exp. Biol. Med. (Maywood, NJ, U. S.)"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib23","first-page":"483","article-title":"Synergistic effect of sulfadiazine and daraprim against toxoplasmosis in the mouse","volume":"3","author":"Eyles","year":"1953","journal-title":"Antibiot. Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115885_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1128\/AAC.32.4.524","article-title":"In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii","volume":"32","author":"Chang","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115885_bib25","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1128\/AAC.31.7.1147","article-title":"Effect of roxithromycin on acute toxoplasmosis in mice","volume":"31","author":"Chang","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"20","key":"10.1016\/j.ejmech.2023.115885_bib26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM197405162902003","article-title":"Congenital toxoplasmosis. A prospective study of 378 pregnancies","volume":"290","author":"Desmonts","year":"1974","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1128\/AAC.46.5.1163-1173.2002","article-title":"Antiparasitic agent atovaquone","volume":"46","author":"Baggish","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115885_bib28","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1073\/pnas.89.23.11126","article-title":"Requirement for coenzyme Q in plasma membrane electron transport","volume":"89","author":"Sun","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(00)00184-5","article-title":"Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance","volume":"108","author":"McFadden","year":"2000","journal-title":"Mol. Biochem. Parasotol."},{"issue":"s4","key":"10.1016\/j.ejmech.2023.115885_bib30","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1086\/430785","article-title":"Drug resistance hampers our capacity to roll back malaria","volume":"41","author":"Olliaro","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2023.115885_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0014-5793(03)00483-6","article-title":"Microbial isoprenoid biosynthesis and human \u03b3\u03b4 T cell activation","volume":"544","author":"Eberl","year":"2003","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1021\/cr60276a002","article-title":"Biosynthesis of monoterpenes","volume":"73","author":"Banthorpe","year":"1972","journal-title":"Chem. Rev."},{"issue":"9\u201310","key":"10.1016\/j.ejmech.2023.115885_bib33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2007.03.016","article-title":"Mevalonate pathway: a review of clinical and therapeutical implications","volume":"40","author":"Buhaescu","year":"2007","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cmdc.201800693","article-title":"The role of the phosphorus atom in drug design","volume":"14","author":"Rodriguez","year":"2019","journal-title":"ChemMedChem"},{"issue":"S1","key":"10.1016\/j.ejmech.2023.115885_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/clc.4960261307","article-title":"Treating hypercholesterolemia: looking forward","volume":"26","author":"Gotto","year":"2003","journal-title":"Clin. Cardiol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ejmech.2023.115885_bib37","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis \u2014 where do we go from here?","volume":"366","author":"Whitaker","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5433","key":"10.1016\/j.ejmech.2023.115885_bib38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.285.5433.1573","article-title":"Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs","volume":"285","author":"Jomaa","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.18388\/abp.2001_3901","article-title":"Isoprenoid biosynthesis via 1-deoxy-D-xylulose 5-phosphate\/2-C-methyl-D-erythritol 4-phosphate (DOXP\/MEP) pathway","volume":"48","author":"Wanke","year":"2001","journal-title":"Acta Biochim. Pol."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115885_bib40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20110039","article-title":"Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii","volume":"208","author":"Nair","year":"2011","journal-title":"J. Exp. Med."},{"issue":"42","key":"10.1016\/j.ejmech.2023.115885_bib41","doi-asserted-by":"crossref","first-page":"30804","DOI":"10.1074\/jbc.M703178200","article-title":"The farnesyl-diphosphate\/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates","volume":"282","author":"Ling","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"38","key":"10.1016\/j.ejmech.2023.115885_bib42","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1021\/bi3005335","article-title":"The N-terminus and the chain-length determination domain play a role in the length of the isoprenoid product of the bifunctional Toxoplasma gondii farnesyl diphosphate synthase","volume":"51","author":"Li","year":"2012","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.abb.2010.09.028","article-title":"Enzymes of the mevalonate pathway of isoprenoid biosynthesis","volume":"505","author":"Miziorko","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115885_bib44","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/ar100026v","article-title":"Targeting isoprenoid biosynthesis for drug discovery","volume":"43","author":"Oldfield","year":"2010","journal-title":"Acc. Chem. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/14728222.12.3.253","article-title":"Targeting the isoprenoid pathway of Toxoplasma gondii","volume":"12","author":"Moreno","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.ejmech.2023.115885_bib46","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nchembio818","article-title":"Therapeutic intervention based on protein prenylation and associated modifications","volume":"2","author":"Gelb","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115885_bib47","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.2174\/1381612043384006","article-title":"The MEP pathway: a new target for the development of herbicides, antibiotics and antimalarial drugs","volume":"10","author":"Rodriguez-Concepcion","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/17460441.2016.1143814","article-title":"Approaches for designing new potent inhibitors of farnesyl pyrophosphate synthase","volume":"11","author":"Rodriguez","year":"2016","journal-title":"Expet Opin. Drug Discov."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib49","first-page":"99","article-title":"Biosynthetic pathways of plastid-derived organelles as potential drug targets against parasitic apicomplexa","volume":"3","author":"Seeber","year":"2003","journal-title":"Curr. Drug Targets: Immune, Endocr. Metab. Disord."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115885_bib50","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/138161208784041105","article-title":"The plastid-like organelle of apicomplexan parasites as drug target","volume":"14","author":"Wiesner","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"issue":"10074","key":"10.1016\/j.ejmech.2023.115885_bib51","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(17)30718-3","article-title":"Safety and efficacy of statins","volume":"389","author":"Thompson","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejmech.2023.115885_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003665","article-title":"Toxoplasma gondii relies on both host and parasite isoprenoids and can be rendered sensitive to atorvastatin","volume":"9","author":"Li","year":"2013","journal-title":"PLoS Pathog."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115885_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02628-16","article-title":"Synergistic activity between statins and bisphosphonates against acute experimental toxoplasmosis","volume":"61","author":"Li","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm0002578","article-title":"Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy","volume":"44","author":"Martin","year":"2001","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib55","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/AAC.46.3.929-931.2002","article-title":"In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii","volume":"46","author":"Yardley","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115885_bib56","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1021\/jm040132t","article-title":"Bisphosphonate inhibitors of Toxoplasma gondii growth: in vitro, QSAR, and in vivo investigations","volume":"48","author":"Ling","year":"2005","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib57","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1016\/j.bmc.2007.12.010","article-title":"Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase","volume":"16","author":"Szajnman","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115885_bib58","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bmc.2011.02.037","article-title":"Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase","volume":"19","author":"Rosso","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib59","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1006\/bbrc.2001.5009","article-title":"31P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth","volume":"284","author":"Moreno","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"s","key":"10.1016\/j.ejmech.2023.115885_bib60","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.mito.2007.03.007","article-title":"Endogenous synthesis of coenzyme Q in eukaryotes","volume":"7","author":"Tran","year":"2007","journal-title":"Mitochondrion"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib61","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.bbabio.2012.03.025","article-title":"Heme A biosynthesis","volume":"1817","author":"Hederstedt","year":"2012","journal-title":"Biochimica et Biophysica Acta (BBA) Bioenergetics"},{"issue":"47","key":"10.1016\/j.ejmech.2023.115885_bib62","doi-asserted-by":"crossref","first-page":"31040","DOI":"10.1074\/jbc.273.47.31040","article-title":"Respiration and oxidative phosphorylation in the apicomplexan parasite Toxoplasma gondii","volume":"273","author":"Vercesi","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"39","key":"10.1016\/j.ejmech.2023.115885_bib63","doi-asserted-by":"crossref","first-page":"15936","DOI":"10.1073\/pnas.1208069109","article-title":"Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis","volume":"109","author":"Doggett","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115885_bib64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fcimb.2020.00203","article-title":"Potent tetrahydroquinolone eliminates apicomplexan parasites","volume":"10","author":"McPhillie","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01966-22","article-title":"The heptaprenyl diphosphate synthase (Coq1) is the target of a lipophilic bisphosphonate that protects mice against Toxoplasma gondii infection","volume":"13","author":"Sleda","year":"2022","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib67","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"issue":"17","key":"10.1016\/j.ejmech.2023.115885_bib68","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1517\/14656566.8.17.3061","article-title":"Atorvastatin and statins in the treatment of heart failure","volume":"8","author":"Horwich","year":"2007","journal-title":"Expet Opin. Pharmacother."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115885_bib69","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1021\/jm300425y","article-title":"Design, synthesis, calorimetry, and crystallographic analysis of 2-alkylaminoethyl-1,1-bisphosphonates as inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase","volume":"55","author":"Aripirala","year":"2012","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01590-16","article-title":"In vitro and in vivo activities of sulfur- containing linear bisphosphonates against apicomplexan parasites","volume":"61","author":"Szajnman","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115885_bib71","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ejmech.2012.12.015","article-title":"Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents","volume":"60","author":"Recher","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115885_bib72","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cmdc.201600505","article-title":"Activity of fluorine-containing analogues of WC-9 and structurally related analogues against two intracellular parasites: Trypanosoma cruzi and Toxoplasma gondii","volume":"11","author":"Chao","year":"2016","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1083\/jcb.149.1.167","article-title":"Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition","volume":"149","author":"Coppens","year":"2000","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib74","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1128\/AAC.38.5.1144","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes","volume":"38","author":"Grellier","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115885_bib75","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.01330-06","article-title":"Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum","volume":"51","author":"Pradines","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115885_bib76","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/AAC.02460-12","article-title":"Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth","volume":"57","author":"Bessoff","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib77","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijantimicag.2008.07.026","article-title":"Statins inhibit Toxoplasma gondii multiplication in macrophages in vitro","volume":"33","author":"Cortez","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ar7000843","article-title":"Hybrid molecules with a dual mode of action: dream or reality?","volume":"41","author":"Meunier","year":"2008","journal-title":"Acc. Chem. Res."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115885_bib79","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1016\/j.bmcl.2015.04.092","article-title":"Prostate tumor specific peptide-peptoid hybrid prodrugs","volume":"25","author":"Lee","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115885_bib80","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/IAI.73.2.695-702.2005","article-title":"Bioluminescence imaging of Toxoplasma gondii infection in living mice reveals dramatic differences between strains","volume":"73","author":"Saeij","year":"2005","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib82","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0005-2760(96)00064-1","article-title":"Polyprenyl diphosphate synthase essentially defines the length of the side chain of ubiquinone","volume":"1302","author":"Okada","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2023.115885_bib83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-9857-9_2","article-title":"ToxoDB: functional genomics resource for Toxoplasma and related organisms","volume":"2071","author":"Harb","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115885_bib84","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00018-018-2808-x","article-title":"A latent ability to persist: differentiation in Toxoplasma gondii","volume":"75","author":"Jeffers","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115885_bib85","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1371\/journal.ppat.0020105","article-title":"Changes in the expression of human cell division autoantigen-1 influence Toxoplasma gondii growth and development","volume":"2","author":"Radke","year":"2006","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/prot.20754","article-title":"Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design","volume":"62","author":"Gabelli","year":"2006","journal-title":"Proteins"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ceca.2011.05.012","article-title":"Acidocalcisomes","volume":"50","author":"Docampo","year":"2011","journal-title":"Cell Calcium"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115885_bib88","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1021\/cr00062a002","article-title":"Structure-activity relationships of dihydrofolated reductase inhibitors","volume":"84","author":"Blaney","year":"1984","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib89","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41598-018-19549-x","article-title":"Plasmodium dihydrofolate reductase is a second enzyme target for the antimalarial action of triclosan","volume":"8","author":"Bilsland","year":"2018","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115885_bib90","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1021\/jm0306327","article-title":"Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors","volume":"47","author":"Gangjee","year":"2004","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115885_bib91","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1021\/jm990331q","article-title":"Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2,4-diaminopteridine analogues with a bridged diarylamine side chain","volume":"42","author":"Rosowsky","year":"1999","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib92","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1021\/jm030438k","article-title":"New 2,4-diamino-5-(2\u2018,5\u2018-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity","volume":"47","author":"Rosowsky","year":"2004","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115885_bib93","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1021\/jm020466n","article-title":"Further studies on 2,4-diamino-5-(2\u2018,5\u2018-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS","volume":"46","author":"Rosowsky","year":"2003","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115885_bib94","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1021\/jm0581718","article-title":"Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with \u03c9-carboxyalkoxy or \u03c9-aarboxy-1-alkynyl substitution in the side chain","volume":"48","author":"Chan","year":"2005","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib95","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/prot.21201","article-title":"Towards in silico lead optimization: scores from ensembles of protein\/ligand conformations reliably correlate with biological activity","volume":"66","author":"Popov","year":"2007","journal-title":"Proteins"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib96","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/jm061027h","article-title":"Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis","volume":"50","author":"Pelphrey","year":"2007","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115885_bib97","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/jm8006933","article-title":"Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates","volume":"51","author":"Gangjee","year":"2008","journal-title":"J. Med. Chem."},{"issue":"45","key":"10.1016\/j.ejmech.2023.115885_bib98","doi-asserted-by":"crossref","first-page":"43126","DOI":"10.1074\/jbc.M206523200","article-title":"Mechanistic characterization of Toxoplasma gondii thymidylate synthase (TS-DHFR)-dihydrofolate reductase","volume":"277","author":"Johnson","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115885_bib99","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1016\/j.bmcl.2014.07.049","article-title":"Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase\u2013dihydrofolate reductase","volume":"24","author":"Kumar","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"15","key":"10.1016\/j.ejmech.2023.115885_bib100","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1021\/jm900490a","article-title":"Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents","volume":"52","author":"Gangjee","year":"2009","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib101","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1021\/acs.jmedchem.8b01754","article-title":"Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis","volume":"62","author":"Hopper","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115885_bib102","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.chom.2010.09.002","article-title":"Functional dissection of the apicomplexan glideosome molecular architecture","volume":"8","author":"Fr\u00e9nal","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"11","key":"10.1016\/j.ejmech.2023.115885_bib103","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrmicro.2017.86","article-title":"Gliding motility powers invasion and egress in apicomplexa","volume":"15","author":"Fr\u00e9nal","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115885_bib104","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1369-5274(03)00091-2","article-title":"Calcium regulation in protozoan parasites","volume":"6","author":"Moreno","year":"2003","journal-title":"Curr. Opin. Microbiol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3390\/ijms22010469","article-title":"Intracellular Ca2+ signaling in protozoan parasites: an overview with a focus on mitochondria","volume":"22","author":"Scarpelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib106","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nsmb.1818","article-title":"Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors","volume":"17","author":"Ojo","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib107","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nmeth764","article-title":"A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases","volume":"2","author":"Zhang","year":"2005","journal-title":"Nat. Methods"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115885_bib108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/ml100096t","article-title":"Discovery of potent and selective inhibitors of CDPK1 from C. parvum and T. gondii","volume":"1","author":"Murphy","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib109","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1021\/jm201713h","article-title":"Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-Toxoplasma activity","volume":"55","author":"Johnson","year":"2012","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115885_bib110","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1021\/acs.jmedchem.7b01192","article-title":"Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii","volume":"60","author":"Rutaganira","year":"2017","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115885_bib111","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1021\/acs.jmedchem.0c00419","article-title":"Optimizing pyrazolopyrimidine inhibitors of calcium dependent protein kinase 1 for treatment of acute and chronic toxoplasmosis","volume":"63","author":"Janetka","year":"2020","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2023.115885_bib112","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1016\/j.bmcl.2012.06.050","article-title":"Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1","volume":"22","author":"Zhang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib113","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jit522","article-title":"A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation","volume":"209","author":"Ojo","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115885_bib114","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijpddr.2021.05.001","article-title":"In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts","volume":"16","author":"Imhof","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ejmech.2023.115885_bib115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejmech.2014.08.046","article-title":"Design, synthesis and biological characterization of thiazolidin-4-one derivatives as promising inhibitors of Toxoplasma gondii","volume":"86","author":"D'Ascenzio","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115885_bib116","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpddr.2021.05.004","article-title":"In vitro evaluation of new 4-thiazolidinones on invasion and growth of Toxoplasma gondii","volume":"16","author":"Molina","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ejmech.2023.115885_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112628","article-title":"Histone deacetylase inhibitor based prodrugs","volume":"203","author":"Fan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115885_bib118","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1021\/acsmedchemlett.9b00560","article-title":"Structural and in vivo characterization of tubastatin A, a widely used histone deacetylase 6 inhibitor","volume":"11","author":"Shen","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib119","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncponc0106","article-title":"Drug insight: histone deacetylase inhibitors\u2014development of the new targeted anticancer agent suberoylanilide hydroxamic acid","volume":"2","author":"Kelly","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.ejmech.2023.115885_bib120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpddr.2020.12.003","article-title":"HDAC inhibitors tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics","volume":"15","author":"Araujo-Silva","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib121","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/jo016088w","article-title":"Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal \u03b1-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities","volume":"67","author":"Singh","year":"2002","journal-title":"J. Org. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115885_bib122","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1021\/ol016240g","article-title":"Structure, histone deacetylase, and antiprotozoal activities of apicidins B and C, congeners of apicidin with proline and valine substitutions","volume":"3","author":"Singh","year":"2001","journal-title":"Org. Lett."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115885_bib123","doi-asserted-by":"crossref","first-page":"13143","DOI":"10.1073\/pnas.93.23.13143","article-title":"Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase","volume":"93","author":"Darkin-Rattray","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib124","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/0929867013373787","article-title":"Histone deacetylase: a target for antiproliferative and antiprotozoal agents","volume":"8","author":"Meinke","year":"2001","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.7164\/antibiotics.56.72","article-title":"Taxonomy, fermentation, isolation and biological activities","volume":"56","author":"Mori","year":"2003","journal-title":"J. Antibiot."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115885_bib126","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1021\/ol050991r","article-title":"Total synthesis of cyclic tetrapeptide FR235222, a potent immunosuppressant that inhibits mammalian histone deacetylases","volume":"7","author":"Xie","year":"2005","journal-title":"Org. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115885_bib127","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20082826","article-title":"Drug inhibition of HDAC3 and epigenetic control of differentiation in apicomplexa parasites","volume":"206","author":"Bougdour","year":"2009","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115885_bib128","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/AAC.00462-10","article-title":"Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds","volume":"54","author":"Maubon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115885_bib129","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.3390\/molecules26247506","article-title":"Crossing of the cystic barriers of Toxoplasma gondii by the fluorescent coumarin tetra-cyclopeptide","volume":"26","author":"Dard","year":"2021","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.pt.2016.10.002","article-title":"Is the mitochondrion a good malaria drug target?","volume":"33","author":"Goodman","year":"2017","journal-title":"Trends Parasitol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115885_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009301","article-title":"Complexome profile of Toxoplasma gondii mitochondria identifies divergent subunits of respiratory chain complexes including new subunits of cytochrome Bc1 complex","volume":"17","author":"Maclean","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2023.115885_bib132","article-title":"Two small-molecule inhibitors of Toxoplasma gondii proliferation in vitro","volume":"13","author":"Hua","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib133","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0166-6851(01)00284-5","article-title":"Defining the cell cycle for the tachyzoite stage of Toxoplasma gondii","volume":"115","author":"Radke","year":"2001","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2023.115885_bib134","first-page":"3320","article-title":"Dynamics of the Toxoplasma gondii inner membrane complex","volume":"127","author":"Ouologuem","year":"2014","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115885_bib135","doi-asserted-by":"crossref","first-page":"e4288","DOI":"10.21769\/BioProtoc.4288","article-title":"Real-time analysis of mitochondrial electron transport chain function in Toxoplasma gondii parasites using a seahorse XFe96 extracellular flux analyzer","volume":"12","author":"Hayward","year":"2022","journal-title":"Bio-Protocol"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009211","article-title":"Divergent features of the coenzyme Q:cytochrome c oxidoreductase complex in Toxoplasma gondii parasites","volume":"17","author":"Hayward","year":"2021","journal-title":"PLoS Pathog."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115885_bib137","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178203","article-title":"Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites","volume":"12","author":"Murata","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib139","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00436-017-5698-1","article-title":"Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents","volume":"117","author":"Adeyemi","year":"2018","journal-title":"Parasitol. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115885_bib140","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00042-15","article-title":"Drug repurposing screening identifies novel compounds that effectively inhibit Toxoplasma gondii growth","volume":"1","author":"Dittmar","year":"2016","journal-title":"mSphere"},{"issue":"14","key":"10.1016\/j.ejmech.2023.115885_bib141","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1055\/s-0030-1270933","article-title":"Antiplasmodial and antitrypanosomal activity of tanshinone-type diterpenoids from Salvia miltiorrhiza","volume":"77","author":"\u015alusarczyk","year":"2011","journal-title":"Planta Med."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib142","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1128\/AAC.01823-13","article-title":"Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection","volume":"58","author":"Doggett","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115885_bib143","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1021\/jm3007596","article-title":"Salicylanilide inhibitors of Toxoplasma gondii","volume":"55","author":"Fomovska","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115885_bib144","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fcimb.2018.00352","article-title":"CSGID solves structures and identifies phenotypes for five enzymes in Toxoplasma gondii","volume":"8","author":"Lykins","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115885_bib145","doi-asserted-by":"crossref","DOI":"10.1038\/srep29179","article-title":"New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections","volume":"6","author":"McPhillie","year":"2016","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115885_bib146","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nrd2684","article-title":"Genomic-scale prioritization of drug targets: the TDR targets database","volume":"7","author":"Ag\u00fcero","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"D1","key":"10.1016\/j.ejmech.2023.115885_bib147","doi-asserted-by":"crossref","first-page":"D1118","DOI":"10.1093\/nar\/gkr1053","article-title":"TDR targets: a chemogenomics resource for neglected diseases","volume":"40","author":"Magari\u00f1os","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115885_bib148","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.cell.2016.08.019","article-title":"A genome-wide CRISPR screen in Toxoplasma identifies essential apicomplexan genes","volume":"166","author":"Sidik","year":"2016","journal-title":"Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:53:02Z","timestamp":1778676782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":148,"alternative-id":["S0223523423008528"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115885","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An updated review of chemical compounds with anti-Toxoplasma gondii activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115885"}}